Skip to main content
. 2024 Mar 28;38(9):1748–1754. doi: 10.1038/s41433-024-03014-3

Table 1.

Summary of the demographic characteristics and systemic features of all cases.

Case Gender Age at diagnosis Haematologic disorder Mutation Systemic inflammation features & survival Treatment
1 M 87 Macrocytic anaemia Valine

None

Alive

GCS
2 M 80 MDS Splice Acceptor Site

Recurrent fever, SSS, GGOs and pleural effusion, laryngitis, sinus vein thrombosis

Deceased

GCS, TOC
3 M 74 MDS Leucine

Recurrent fever. SSS, aortitis on CT, cutaneous vasculitis, severe drug reaction to anakinra, GGOs and pleural effusion

Alive

GCS, HCQ, MTX, COL, DAP, ANA
4 M 75 MDS Valine

Recurrent fever, SSS, severe drug reaction to anakinra, DVT, superficial thrombophlebtits, asymptomatic GGOs and pleural effusion

Alive

GCS, TOC, COL
5 M 75 MDS Valine

Recurrent fever, SSS, severe drug reaction to anakinra, PAN like syndrome, superficial thrombophlebtits, GGOs and pleural effusion

Deceased

GCS, MTX, CsA, CYC, ANA, TOC, CAN
6 M 76 MDS Valine

Recurrent fever, SSS, myositis, severe symptomatic GGO’s (respiratory failure)

Alive

GCS, TOC
7a M 75 MDS NA

Recurrent fever, SSS, DVT, superficial thrombophlebitis, pericarditis, symptomatic GGOs

Deceased

GCS
8a M 88 MDS NA

Recurrent fever, SSS, recurrent ear chondritis, motor neuropathy

Deceased

GCS, MTX

M male, MDS myelodysplastic disorder, PAN polyarteritis nodosa, SSS skin sweet syndrome, GGO pulmonary ground glass opacity, DVT deep vein thrombosis, GCS glucocorticosteroids, TOC tocilizumab, HCQ hydroxychloroquine, MTX methotrexate, COL colchicine, DAP dapsone, ANA anakinra, CsA cyclosporine A, CYC cyclophosphamide, CAN canakinumab.

aCase 7 and 8 considered presumed VEXAS. Genomic sequencing was not performed and post-mortem revision of the bone marrow samples demonstrated vacuoles.